Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-IVIG in severe COVID-19 patients
NCT04891172Phase 3Unknown
- Sponsor
- Dow University of Health Sciences
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Anti-COVID-19 intravenous immunoglobulin in coronavirus disease 2019 (COVID-19), sponsored by Dow University of Health Sciences. Status: unknown.
02
Drugs
Anti-COVID-19 intravenous immunoglobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04891172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891172.